DeepMed Research

Incyte

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 2.5K

Market Cap: $12.6B

Website

Introduction: Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Clinical Trials

An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Conditions: Graft-versus-host Disease (GVHD)

First Posted Date: 2017-05-10

Last Posted Date: 2022-06-07

Lead Sponsor: Incyte Corporation

Registration Number: NCT03147742

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Rutgers Cancer Institute, New Brunswick, New Jersey, United States
🇺🇸
Texas Oncology, Dallas, Texas, United States

and more 30 locations

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Phase 1

Terminated

Conditions: Hepatocellular Carcinoma (HCC)
Cholangiocarcinoma
Esophageal Cancer
Nasopharyngeal Cancer
Ovarian Cancer
Solid Tumors

Interventions: Drug: INCB062079

First Posted Date: 2017-05-09

Last Posted Date: 2020-07-15

Lead Sponsor: Incyte Corporation

Target Recruit Count: 25

Registration Number: NCT03144661

Locations: 🇧🇪
University Hospital (UZ) Leuven, Leuven, Belgium
🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium

and more 3 locations

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

Phase 2

Completed

Conditions: MPN (Myeloproliferative Neoplasms)

Interventions: Drug: Itacitinib
Drug: Ruxolitinib

First Posted Date: 2017-05-09

Last Posted Date: 2022-06-16

Lead Sponsor: Incyte Corporation

Target Recruit Count: 23

Registration Number: NCT03144687

Locations: 🇺🇸
Texas Oncology - Tyler, Tyler, Texas, United States
🇦🇹
Paracelsus Medical University Salzburg, Salzburg, Austria
🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

and more 22 locations

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Parsaclisib

First Posted Date: 2017-05-09

Last Posted Date: 2025-05-16

Lead Sponsor: Incyte Corporation

Target Recruit Count: 110

Registration Number: NCT03144674

Locations: 🇺🇸
Arizona Oncology Associates, Tempe, Arizona, United States
🇺🇸
Sansum Clinic, Santa Barbara, California, United States
🇺🇸
UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States

and more 82 locations

GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease

Phase 3

Completed

Conditions: Graft-versus-host Disease (GVHD)

Interventions: Drug: Placebo
Drug: Itacitinib
Drug: Prednisone
Drug: Methylprednisolone

First Posted Date: 2017-05-04

Last Posted Date: 2021-08-11

Lead Sponsor: Incyte Corporation

Target Recruit Count: 439

Registration Number: NCT03139604

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California, United States
🇺🇸
Advocate Lutheran General Hospital - Oncology Specialists SC, Park Ridge, Illinois, United States

and more 126 locations

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

Phase 1

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: INCB059872

First Posted Date: 2017-04-27

Last Posted Date: 2019-10-28

Lead Sponsor: Incyte Corporation

Target Recruit Count: 12

Registration Number: NCT03132324

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Acevedo Clinical Research Associates, Miami, Florida, United States
🇺🇸
Advanced Pharma, Miami, Florida, United States

and more 4 locations

A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Parsaclisib

First Posted Date: 2017-04-24

Last Posted Date: 2025-03-14

Lead Sponsor: Incyte Corporation

Target Recruit Count: 126

Registration Number: NCT03126019

Locations: 🇺🇸
Florida Cancer Specialists & Research Institute, Fort Myers, Florida, United States
🇺🇸
Hattiesburg Clinic Hematology, Hattiesburg, Mississippi, United States
🇺🇸
University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States

and more 80 locations

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Phase 2

Terminated

Conditions: MPN (Myeloproliferative Neoplasms)

Interventions: Drug: Ruxolitinib
Drug: Anagrelide
Drug: Placebo

First Posted Date: 2017-04-21

Last Posted Date: 2021-11-19

Lead Sponsor: Incyte Corporation

Target Recruit Count: 12

Registration Number: NCT03123588

Locations: 🇺🇸
Columbia Weill Cornell Cancer Centers - Herbert Irving Comprehensive Cancer Center (HICCC), New York, New York, United States
🇺🇸
Ventura County Hematology-Oncology Specialists, Oxnard, California, United States
🇺🇸
Tift Regional, Tifton, Georgia, United States

and more 23 locations

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Phase 3

Completed

Conditions: Graft-versus-host Disease (GVHD)

Interventions: Drug: Ruxolitinib
Drug: Extracorporeal photopheresis (ECP)
Drug: Low-dose methotrexate (MTX)
Drug: Mycophenolate mofetil (MMF)
Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)
Drug: Infliximab
Drug: Rituximab
Drug: Pentostatin
Drug: Imatinib
Drug: Ibrutinib

First Posted Date: 2017-04-13

Last Posted Date: 2023-07-18

Lead Sponsor: Incyte Corporation

Target Recruit Count: 330

Registration Number: NCT03112603

Locations: 🇵🇷
Incyte Investigative Site, Ponce, Puerto Rico
🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
🇷🇴
Novartis Investigational Site, Bucharest, Romania

A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo

Phase 2

Completed

Conditions: Vitiligo

Interventions: Drug: Ruxolitinib cream
Drug: Vehicle cream

First Posted Date: 2017-04-04

Last Posted Date: 2022-11-17

Lead Sponsor: Incyte Corporation

Target Recruit Count: 157

Registration Number: NCT03099304

Locations: 🇺🇸
NORTHWESTERN UNIVERSITY, 676 N Saint Clair, Chicago, Illinois, United States
🇺🇸
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE DERMATOLOGY, 969 N. Mason Road, Saint Louis, Missouri, United States
🇺🇸
CENTRAL SOONER RESEARCH, 900 N Porter Ave, Norman, Oklahoma, United States

and more 23 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy